Objective:To compare the efficacy of sugammadex versus neostigmine on reversal of rocuronium-induced residual neuromuscular blockade in patients undergoing renal transplantation. Methods:The clinical data of patients undergoing kidney transplantation from donation after cardiac death in our hospital from January 2018 to December 2020 were retrospectively analyzed.Patients were divided into sugammadex group (group S) and neostigmine group (group N) according to the use of muscle relaxant antagonists.The onset time of antagonism, time of tracheal extubation, and time of postanesthesia care unit stay were recorded.The creatinine clearance rate was recorded before operation and at 1, 3, 5 and 7 days after operation.The occurrence of postoperative complications was recorded.Results:A total of 603 patients were enrolled in this study, with 278 patients in group S and 325 patients in group N. Compared with group N, the onset time of antagonism, time of extubation , and time of postanesthesia care unit stay were significantly shortened, the incidence of hypoxemia within 24 h after surgery and pulmonary infection occurred within 7 days after surgery was decreased ( P<0.05), and no significant change was found in the creatinine clearance rate at each time point and incidence of postoperative cardiovascular complications and graft complications in group S ( P>0.05). Conclusion:Compared with neostigmine, sugammadex can reverse rocuronium-induced residual neuromuscular blockade more quickly, which is helpful for early recovery with a higher safety when applied in the patients undergoing renal transplantation.

Objective To observe the correlation between analgesia nociception index (ANI) and hemodynamic changes during laparoscopic surgery after tracheal intubation andto assess the effectiveness of ANI.Methods A multicenter, prospective clinical study was conducted and 284 patients underwent laparoscopic surgery were enrolled. Patients were monitored after entering the operating room. Endotracheal intubation was completed by anesthesia induction with target controlled remifentanil and propofol, after arterial and central venous catheterization were improved. Anesthesia was maintainedby continued propofol and remifentanil target controlled infusion.The ANI value, systolic pressure, heart rate of 5 minutes after completion of the entry, completion of the first trocar and completion of all the trocars were recorded. The ANI values and the changes in the vital signs (systolicblood pressure and heart rate) were observed during the laparoscopic operation, and the effectiveness of the ANI index to assess the pain caused by the insertion of a laparoscope trocar was evaluated. Results (1) The area under the ANI curve was positively correlated with the one under thesystolic blood pressure and the heart rate curve during the period from cutting the skin to 5 mins after completing all the trocars (P < 0.05). (2) ANI was negatively correlated with SBP and HR when skin incision and the first trocar were completed (P < 0.001). Conclusions The changes in ANI were in accordance with the balance between analgesic and noxious stimuli, and negatively correlated with the changes insystolic blood pressure and heart rate. ANI could accurately evaluate the pain situation when the card was inserted.

Objective:To evaluate the effect of sugammadex on the long-term prognosis in the patients undergoing kidney transplantation.Methods:American Society of Anesthesiologists Physical Status classification Ⅲ or Ⅳ patients of either sex, aged 18-64 yr, underwent donation after cardiac death renal transplantation from January 1, 2018 to October 31, 2021, were included in this study. Their clinical data were retrospectively analyzed, and then the patients were divided into 2 groups: sugammadex group (group S) and control group (group C). The complications at 1 yr after surgery and patient/graft survival at 1 and 3 yr after surgery were recorded.Results:A total of 645 patients were finally enrolled in this study, with 319 patients in group S and 326 patients in group C. There was no significant difference in the incidence of postoperative complications within 1 yr after surgery between two groups ( P>0.05). The overall patient survival rate at 1 and 3 yr after surgery were 94.7% and 92.8% respectively, and the death-censored graft survival at 1 and 3 yr after surgery were 94.4% and 89.4% respectively in group S. The overall patient survival rate at 1 and 3 yr after surgery were 96.6% and 94.7% respectively, and the death-censored graft survival at 1 and 3 yr after surgery were 93.9% and 88.6% respectively in group C. There was no significant difference in patient/graft survival rate between two groups ( P>0.05). Conclusions:Sugammadex has no obvious effect on the long-term prognosis in the patients undergoing kidney transplantation.